The Contractor shall maintain a dynamic raw material supply chain of embryonated hen eggs, for manufacturing of its pandemic influenza vaccine. The Contractor shall provide a domestic (Contiguous United States) network of incubation facilities and flocks, to provide a year-round supply of embryonated eggs developed specifically for a FDA-licensed seasonal and possible pandemic influenza vaccine. In addition, the Contractor shall have the ability to produce a minimum of ten (10) million monovalent influenza vaccine final finished container, including losses, doses per week, in the case of a declared public health emergency.
The Egg Supply program also requires an Avian Influenza (High or Low Pathogenicity) Plan for the Contractor’s sites and personnel, as well as a plan for dynamic testing of flocks and facilities to mitigate risks during High (or Low) Pathogenicity Avian Influenza conditions.
